Drugs / CD19X CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07447726 | Apr 2026 → Jan 2028 expected | large B-cell lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19X CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07447726 ↗ |
| Modality | Cell therapy | “CAR-T cell infusion” NCT07447726 ↗ |